Pulmatrix Shifts Focus Following Termination of Merger with Cullgen Pulmatrix has announced it will pursue alternative merger opportunities after the termination of its planned merger with Cullgen, stemming from regulatory delays.

Pulmatrix Shifts Focus Following Termination of Merger with Cullgen #USA #Framingham #Pulmatrix #iSPERSE #Cullgen

Pulmatrix Reports Q3 2025 Results and Strategic Divestiture Plans for Inhalation Assets Pulmatrix, Inc. has announced its Q3 2025 financial results and revealed plans for divesting assets, focusing on migraine and respiratory treatments through innovative inhalation technologies.

Pulmatrix Reports Q3 2025 Results and Strategic Divestiture Plans for Inhalation Assets #United_States #Framingham #Pulmatrix #Migraine #iSPERSE

Pulmatrix's Q2 2025 Financial Results and Strategy to Divest Inhalation Assets Pulmatrix, Inc. reveals its financial outcomes for the second quarter of 2025, alongside plans to divest its inhalation technology assets amid a proposed merger.

Pulmatrix's Q2 2025 Financial Results and Strategy to Divest Inhalation Assets #United_States #Framingham #Pulmatrix #iSPERSE #Cullgen

Pulmatrix Reports Financial Results and Plans for Divestment Amid Merger with Cullgen Pulmatrix, Inc. has shared its fourth quarter 2024 financial results, revealing a divestment strategy coinciding with a proposed merger with Cullgen.

Pulmatrix Reports Financial Results and Plans for Divestment Amid Merger with Cullgen #United_States #Framingham #Pulmatrix #iSPERSE #Cullgen